**SUPPLEMENTARY FILE 2: ESTIMATED VALUE FOR NINTEDANIB VS. PLACEBO IN THE TEST AND RE-TEST**

**Supplementary Table 2.1: Comparison between the estimated values for nintedanib vs. placebo in the test and re-test, non-IPF PF-ILD and SSc-ILD (n=12)**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Indication | Method | Test | Re-test | ∆ | ICC (3,1) individual | ICC (3,1) average |
| Non-IPF PF-ILD | 1-5 scale | 0.4424 | 0.4239 | -4,18% | 0.556 | 0.715 |
| 100-point distribution | 0.5022 | 0.4592 | -8,57% | 0.595 | 0.746 |
| SSc-ILD | 1-5 scale | 0.3446 | 0.3685 | 6,93% | 0.440 | 0.611 |
| 100-point distribution | 0.3977 | 0.3973 | -0,08% | 0.508 | 0.673 |

*Non-IPF PF-ILD*: non-idiopathic progressive fibrosing interstitial lung disease

*SSc-ILD*: systemic sclerosis-associated interstitial lung disease

*ICC*: intra-rater correlation coefficients